<div class="container">

<table style="width: 100%;"><tr>
<td>melanoma</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Melanoma Clinical Trials E1684 and E1690</h2>

<h3>Description</h3>

<p>A dataset for the E1684 clinical trial (1996) and the E1690 clinical trial (2000) conducted to assess the utility of interferon alfa-2b (INF) as an adjuvant therapy following surgery for deep primary or regionally metastatic melanoma.
This dataset contains subjects in disease stage four only, i.e., regional lymph node recurrence at any interval
after appropriate surgery for primary melanoma of any depth.
</p>


<h3>Usage</h3>

<pre><code class="language-R">melanoma
</code></pre>


<h3>Format</h3>

<p>A data frame with 381 rows and 5 variables:
</p>

<dl>
<dt>study</dt>
<dd>
<p>study number (1684 or 1690)</p>
</dd>
<dt>failtime</dt>
<dd>
<p>time to relapse in years</p>
</dd>
<dt>rfscens</dt>
<dd>
<p>censoring indicator for time to relapse (0 = did not relapse, 1 = relapsed)</p>
</dd>
<dt>trt</dt>
<dd>
<p>treatment (1 if IFN and 0 if Observation)</p>
</dd>
<dt>stratum</dt>
<dd>
<p>stratum index (1 if number of positive nodes &lt;= 2 and 2 if number of positive nodes &gt;= 3</p>
</dd>
</dl>
<h3>Source</h3>

<p>Kirkwood, J. M., J. G. Ibrahim, V. K. Sondak, J. Richards, L. E. Flaherty, M. S. Ernstoff, T. J. Smith,
U. Rao, M. Steele, and R. H. Blum (2000, Jun). High- and low-dose interferon alfa-2b in high-risk
melanoma: first analysis of intergroup trial e1690/s9111/c9190. Journal of Clinical Oncology 18 (12),
2444–2458.
</p>
<p>Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum
(1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern
cooperative oncology group trial est 1684. Journal of Clinical Oncology 14, 7–17.
</p>


</div>